Free Trial

Dynavax Technologies Q2 2023 Earnings Report

Dynavax Technologies logo
$13.05 +0.04 (+0.31%)
As of 01/31/2025 04:00 PM Eastern

Dynavax Technologies EPS Results

Actual EPS
$0.03
Consensus EPS
-$0.09
Beat/Miss
Beat by +$0.12
One Year Ago EPS
N/A

Dynavax Technologies Revenue Results

Actual Revenue
$60.25 million
Expected Revenue
$51.03 million
Beat/Miss
Beat by +$9.22 million
YoY Revenue Growth
N/A

Dynavax Technologies Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Dynavax Technologies Earnings Headlines

We recommended Palantir in 2021, now we're recommending this...
Simply put: All the grandiose claims you hear about AI will amount to nothing without one key investment. That's why I believe the biggest AI gains will NOT come from the "Next NVIDIA"... or some obscure AI startup you've never heard of. In fact, I'm convinced the biggest gains will come from one company that - at first glance - has nothing to do with AI at all. It's a Texas-based firm that provides the backbone for the entire $15.7 trillion AI industry.
Dynavax Advances Board Refreshment Program
See More Dynavax Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dynavax Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dynavax Technologies and other key companies, straight to your email.

About Dynavax Technologies

Dynavax Technologies (NASDAQ:DVAX), a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

View Dynavax Technologies Profile

More Earnings Resources from MarketBeat